Farmacia italiana online: acquisto cialis in Italia e Roma senza ricetta.

Abg_

DERMAL FILLER PRODUCT COMPARISON
Manufacturer
Product(s)
Description
Physician
Regulatory Status
Component
ABR-Development
Tricalcium phosphate suspended in hyaluron- 12 mg/ml; for medium wrinkles and lip contour.
18 mg/ml; for deep wrinkles and volume.
27 mgl/ml; for volume augmentation andfacial contouring.
Purified, medical grade polydimethylsiloxane Laboratories, Inc.
oil – 1000 cs. For microdroplet injection.
FDA for retinal detachments,but not for facial filler indica-tions. Off label use only.
Allergan
Purified bovine-based collagen 35 mg/ml x 6.
Purified bovine-based collagen 65 mg/ml x 6.
cross-linked with glutaraldehyde x 6.
*All collagen products contain 0.3% lidocaine.
Purified human-based collagen 35 mg/ml.
*All collagen products contain 0.3% lidocaine.
Non-animal, cross-linked cohesive hyaluronic Non-animal, cross-linked cohesive hyaluronic Non-animal, cross-linked cohesive hyaluronic Non-animal, cross-linked cohesive hyaluronic Non-animal, cross-linked cohesive hyaluronic acid 24 mg/g.
*All Juvéderm ULTRA products contain 0.3%lidocaine.
Non-animal, cross-linked cohesive hyaluronic Anteis S.A.
Non-animal 5 phase cross-linked hyaluronic CE mark. Pending approval inCanada and South Korea.
Artes Medical
20% polymethylmethacrylate (PMMA) – 30 to 50 microns – 80% purified bovine collagen 55.7%) microspheres, 25 – 45 microns, sus-pended in an aquaeous polysaccharide gel(1.3% sodium carboxymethylcellulose USP,6.4% glycerin USP & 36.6% water USP).
BioForm Medical
Generation polyacrylamide gel comprised of (Russia)
BioPolymer
MATRIDEX: synthetic hyaluronic acid sodium GmbH & Co. KG
salt 25 mg, hypromellose 15 mg, positively charged DEAE sephadex particles 25 mg(cross-linked dextran).
MATRIDUR: synthetic stabalized hyaluronic acidsodium salt 25 mg and hypromellose 5 mg.
MATRIGEL: stabalized HA 12.25 mg.
2.5% cross-linked hydrophilic polyacrylamide International A/S
trials under way. For investiga-tional use only in U.S. CE mark-ing: CE 0543 – March 2001.
Sold in more than 30 countriesaround the world.
Dermabiol Institute of
Rhegecoll: 40% bovine collagen from U.S.
Kuhra Vital
(stem cell) 10% polymethacrylate, 15%copolymer 4-G, 15% stabilizer / emulsifier.
Dermatech
acrylic hydrogel (hydroxyethylmetacrylate – HEMA and ethylmetacrylate (EMA) co-polymer particles by volume. DermaLive – 200 mg 45 – 65 micro beads, 14.4 mg HA.
Dermadeep – 200 mg 80 – 110 micro beads,14.4 mg HA.
THE Aesthetic Guide Primary Care Edition Spring 2009 www.mi news.com DERMAL FILLER PRODUCT COMPARISON
Manufacturer
Product(s)
Description
Physician
Regulatory Status
Component
Fascia Biosystems
Human allograft material – fascia, collected with sterile normal saline, 0.5% lidocaine.
are no off-label uses – hence aphysician can use as desired.
FibroGen, Inc.
human collagen type III in saline with lido- and safety study required forregulatory approval of FG-5017is expected to begin in 2005.
FuHua High
Molecular Matter
Company, Ltd.
FzioMed, Inc.
Non-permanent, long lasting, ultra smooth dermal filler, containing no bacterial or ani- mal by-products, no cross-linking chemicals Isolagen, Inc.
Isolagen – autologous cellular system – Laboratories
hyaluronic acid (2.1%) sodium chloride.
MacDermol R – Avian cross-linkedhyaluronic acid (3.4%) chitosan chondroitinsulfate sodium chloride.
Pharmaceutical
NASHA gel – a non-animal hyaluronic acid, stabilized with BDDE. The differentiation is in the size of the NASHA particles, to assure a Restylane Touch – 500,000 particles per ml.
Restylane – 100,000 particles per ml.
Restylane Perlane – 10,000 particles per ml.
Restylane Sub-Q – 1,000 particles per ml.
Mentor Corporation
in conjunction with
double cross-linked (DXL technology).
Puragen Plus contains lidocaine integrated Corporation
0.3% lidocaine integrated directly into theformula.
Merz Pharma
GmbH & Co. KGaA
hyaluronic acid – via biofermentation – Russia and Italy from Anteis SA.
U.S. approval pending.
Nordic Aesthetics
8.4 mg/ml, bi-phasic gel of cross-linked HA (by S&V, Germany)
linked HA (CIS technology), 1 ml and 2 mlsyringes.
24 mg/ml, bi-phasic gel of cross-linked HA micro-particles dispersed in non cross-linkedHA (CIS technology), 1 ml and 2 ml syringes.
24 mg/ml, biphasic gel of cross-linked HA micro-particles dispersed in non cross-linkedHA (CIS technology), 0.5 ml and 1 ml syringes.
12 mg/ml, non cross-linked HA for skin reju- venation and hydration, 2 ml syringe.
Ortho Dermatologics
Aesthetics
collagen – glycation with a natural sugar – solution. Glymatrix technology provides a collagen that extends the benefits for up to THE Aesthetic Guide Primary Care Edition Spring 2009 www.mi news.com DERMAL FILLER PRODUCT COMPARISON
Manufacturer
Product(s)
Description
Physician
Regulatory Status
Component
Polymekon
BIO-ALCAMID – 96% water and 4% synthet- ic reticulate polymer (poly-Alkyl-mide). Lips is soft and compact. Face has the same com-position (it is not a dilution), Body has the same consistency as the Face form, but con- Bioinblue – PVA (polyvinyl alcohol 8%) andwater (92%).
ProCytech SA
Evolution is a mixture of microscopic softspheres of polyvinyl in a viscoelastic gel ofpoly (acrylamide-co-DADMA) gel.
Prollenium Medical
Technologies
Revanesse Ultra – high viscosity, cross-linked, reticulated hyaluronic acid 25 mg,hypromellose 15 mg.
ReDexis – cross-linked reticulated hyaluronicacid 25 mg, hypromellose 15 mg,dextronomer DEAE 25 mg.
NASHA gel – a non-animal hyaluronic acid, stabilized with BDDE. The differentiation is in the size of the NASHA particles, to assure a Restylane Touch – 500,000 particles per ml.
Restylane – 100,000 particles per ml.
Restylane Perlane – 10,000 particles per ml.
Restylane Sub-Q- 1,000 particles per ml.
Rofil / Philoderm
Rofilan – 20 mg/ml cross-linked hyaluronic acid.
Sanofi-Aventis
Poly-L-Lactic acid (PLLA) hydrogel belonging to the family of aliphatic polyesters.
tion and/or correction of thesigns of facial fat loss (lipoatro-phy). Approved in Europe in2000 as NewFill – 2004 asSculptra for facial aesthetic use.
100% hyaluronic acid-based, resorbable and Laboratories
Teosyal KissTeosyal Ultra DeepTeosyal First LinesTeosyal Touch UpTeosyal Meso Uroplasty
Solid silicone microspheres (100 to 400 and 600 µm) suspended in a polyvinylpyrrolidonevector.
THE Aesthetic Guide Primary Care Edition Spring 2009 www.mi news.com

Source: http://www.porownaj-laser.pl/pdf/DermalFiller_Charts_TAGPCsp09v3_050709.pdf

Microsoft word - 2006_0727glaxosmithkline.doc

Unternehmensporträt International GlaxoSmithKline (GB) 27. Juli 2006 Halten (bisher: Halten) Glaxo SmithKline Kurs (LSE): Währung: Hoch (52 Wo.) : Tief (52 Wo.) : Reuters: Marktkap.: Umsatzstärkste Regionen / Sparten Gewinn je Nettodivi- Verschul- Eigenkapital- Nettogewinn dende/Aktie Div.-Rendite dungsgrad • GlaxoSmithKline Pl

Veins for web

AUGUST 2002 / VOLUME 54 / NUMBER 8 ❿ B Y K I M B E R LY R . P O N T I U S New Veins of Application The use of PCD-veined drills on difficult-to-machine materials has expanded beyond their initial applications in the aerospace and electronics sectors. n the late 1980s, the world was in-troduced to such future successes as I Federal Reserve Board Chairman Alan Greenspan, baseba

Copyright © 2010-2014 Pdf Pills Composition